Quantcast

Latest Clinical trial Stories

2014-07-31 08:37:16

ANTWERP, Belgium and LONDON, July 31, 2014 /PRNewswire/ -- genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the incorporation of genae UK in London. The United Kingdom has one of the largest medical device markets in the world. It was valued at USD 8.9 billion in 2012 and it is projected to increase by a CAGR of 6.0% until 2017. Health expenditure was estimated at USD 234 billion in 2012, equal to...

2014-07-30 16:29:33

LEXINGTON, Mass., July 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported second quarter 2014 financial results, and provided other business updates. Second Quarter 2014 Financial Results For the quarter ended June 30, 2014, Synageva reported a net loss of $50.2 million compared to a net loss of $22.1 million for the corresponding quarter of the prior year....

2014-07-30 08:32:52

ENGLEWOOD, Colo., July 30, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a positive written response from the FDA in regards to the company's plans to begin production of Ampion(TM) in our new drug manufacturing facility. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Dr. Vaughan Clift, Ampio's Chief Regulatory Officer explained, "Satisfying the Chemistry, Manufacturing and Controls (CMC) requirements of a Biological License Application...

2014-07-30 08:32:08

Anticipate Topline Data in 6-8 months IRVINE, Calif., July 30, 2014 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001...

2014-07-30 04:21:20

CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, July 30, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two...

2014-07-29 23:15:25

White papers by Clinovo on CDISC Standards for medical devices and cloud-based eClinical technologies have been published in the latest editions of leading pharmaceutical publications Data Basics and Med Device Online Sunnyvale, CA (PRWEB) July 29, 2014 White papers by Clinovo on CDISC Standards for medical devices, and cloud based eClinical technologies, have been published by leading pharmaceutical publications Data Basics and Med Device Online. These follow a long line of white papers...

2014-07-29 23:05:06

MarketReportsOnline.com adds "Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition)" report to its research store. Dallas, Texas (PRWEB) July 29, 2014 This Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical trials for imported drug registration but also introduced...

2014-07-29 08:33:38

NEW YORK, July 29, 2014 /PRNewswire/ -- Recently unveiled at the annual American Society of Clinical Psychopharmacology conference in Hollywood, FL, a new randomized, double-blinded, placebo-controlled human clinical trial conducted by The Brain Institute, at the University of Utah, found that adolescent males experienced increased motor speed and attention after supplementation of citicoline. The trial involved 75 adolescent males over a 28-day period in which the citicoline, a known...

2014-07-29 08:32:50

PLANTATION, Fla., July 29, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C epsilon (PKCe). In preclinical in vivo models, this effect has been shown to play an important role in slowing or reversing AD and restoring cognition, memory and motor skills. The top-line analysis...

2014-07-28 23:04:08

Transparency Market Research has published a new report titled "Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" to its report store. Browse the full report: http://www.transparencymarketresearch.com/e-clinical-solution-software-market.html. Albany, New York (PRWEB) July 28, 2014 According to a new market report published by Transparency Market Research "E-Clinical Solution Software Market- Global Industry...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related